

www.elsevier.com/locate/ejphar

3,7-Bis(2-hydroxyethyl)icaritin, a potent inhibitor of phosphodiesterase-5, prevents monocrotaline-induced pulmonary arterial hypertension via NO/cGMP activation in rats

Tao-Hua Lan, Xiao-Ling Chen, Yun-Shan Wu, Hui-Liang Qiu, Jun-Zhe Li, Xin-Min Ruan, Dan-Ping Xu, Dong-Qun Lin

PII: S0014-2999(18)30222-X
DOI: https://doi.org/10.1016/j.ejphar.2018.04.011
Reference: EJP71760

To appear in: *European Journal of Pharmacology*

Received date: 31 January 2018
Revised date: 10 April 2018
Accepted date: 13 April 2018

Cite this article as: Tao-Hua Lan, Xiao-Ling Chen, Yun-Shan Wu, Hui-Liang Qiu, Jun-Zhe Li, Xin-Min Ruan, Dan-Ping Xu and Dong-Qun Lin, 3,7-Bis(2-hydroxyethyl)icaritin, a potent inhibitor of phosphodiesterase-5, prevents monocrotaline-induced pulmonary arterial hypertension via NO/cGMP activation in rats, *European Journal of Pharmacology,* https://doi.org/10.1016/j.ejphar.2018.04.011

3,7-Bis(2-hydroxyethyl)icaritin, a potent inhibitor of phosphodiesterase-5, prevents monocrotaline-induced pulmonary arterial hypertension via NO/cGMP activation in rats

Tao-Hua Lan[a], Xiao-Ling Chen[a], Yun-Shan Wu[b], Hui-Liang Qiu[a], Jun-Zhe Li[a], Xin-Min Ruan[a], Dan-Ping Xu[a], Dong-Qun Lin[a,*]

[a]Department of Cardiology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, 111 Dade Road, Guangzhou, P. R. China.

[b]Guangdong Provincial Hospital of Chinese Medicine, 111 Dade Road, Guangzhou, P. R. China.

[*]Corresponding author. Dong-Qun Lin, Tel: (86) 2039318582, email: ldqtcm@163.com

Abstract

Pulmonary arterial hypertension (PAH) is a chronic progressive disease which leads to elevated pulmonary arterial pressure and right heart failure.

3,7-Bis(2-hydroxyethyl)icaritin (ICT), an icariin derivatives, was reported to have potent inhibitory activity on phosphodiesterase type 5 (PDE5) which plays a crucial role in the pathogenesis of PAH. The present study was designed to investigate the